Harry Stylli News Today

BIOR | Complete Biora Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Sean...

Progenity Announces Poster Presentations at Digestive Disease Week 2021 Two Abstracts Support Company’s Targeted Therapeutics Program including the Drug Delivery System May 24, 2021 07:30 ET | Source: Progenity, Inc. Progenity, Inc. San Diego, California, UNITED STATES SAN DIEGO, May 24, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the presentation of two posters related to the compa...

Progenity, Inc. (PROG) Q1 2021 Earnings Call Transcript Motley Fool Transcribing © The Motley Fool Logo of jester cap with thought bubble. Progenity, Inc. (NASDAQ: PROG) Operator Good afternoon everyone. Welcome to the Progenity first-quarter 2021 earnings call. [Operator instructions] And later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator instructions] And I will now turn the call over to Robert Uhl, managing director ...

Progenity and Ionis Pharmaceuticals Enter into Agreement for Oral Delivery of Antisense Therapies Share Rare Daily Staff Progenity said it entered an agreement with Ionis Pharmaceuticals to evaluate Progenity’s Oral Biotherapeutics Delivery System for oral systemic delivery of Ionis’ antisense oligonucleotides. Ionis’ novel antisense therapies are designed to target mRNA in a highly specific manner and either decrease disease-causing proteins or increase the production of ...

Progenity Reaches Two Million Test Milestone The company celebrates its ten-year anniversary and looks toward future innovations SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, has reported the completion of two million diagnostic tests by its CLIA-certified and CAP-accredited laboratory in Ann Arbor, Michigan. This notable milestone com...

Progenity Provides Financial Guidance for Full-year 2021 Total 2021 revenue expected to grow by up to 30% 1 Core molecular testing volume expected to grow by up to 16% SAN DIEGO, Jan. 13, 2021 — Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today provided 2021 full-year financial guidance. “The year 2020 proved to be a transitional period for Progenity, especially in light o...

Progenity to Present at the 2021 ICR Conference Progenity to Present at the 2021 ICR Conference SAN DIEGO, Jan. 05, 2021 — Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced its participation in the 2021 ICR Conference. Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of Progenity, will present a company overview on Thursday, January 14, 2021 at 4 p.m. ...